Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

The new shots, made by Moderna and Pfizer-BioNTech, are largely the same as the original mRNA vaccines developed at the start of the pandemic—but they target KP.2, a different strain of the ...

Because viruses evolve as they infect people, the CDC has recommended updated covid vaccines each year. Last fall’s booster was designed to target the omicron variant circulating in 2023. This year, ...

The U.S. Food and Drug Administration recently green-lit new 2024-25 COVID-19 vaccinations ahead of the fall and winter seasons, when respiratory viruses spread more rapidly within communities.

In a significant breakthrough, the world’s first mRNA lung cancer vaccine trials have been launched across seven countries, ...

The new COVID-19 vaccines based on mRNA technology are no exception. But one risk associated with them—myocarditis, especially for young men—has raised concerns among the public. A new study ...

WHAT ARE THE BIG CHANGES? LISTEN, MOST THINGS ARE THE SAME. MRNA VACCINES. WE KNOW BILLIONS OF PEOPLE HAVE GOTTEN IT AND WHAT’S CHANGING IS THE TYPE. SO IT’S GOING TO BE CP2, WHICH IS THE ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) ...

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress ...